Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 4/20 | 0.58 |
| ▸ | MMP2 | P08253 | 4/20 | 0.58 |
| ▸ | GBA2 | Q9HCG7 | 1/20 | 0.40 |
| ▸ | MMP1 | P03956 | 2/20 | 0.40 |
| ▸ | MMP3 | P08254 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | PEPD | P12955 | 2/20 | 0.35 |
| ▸ | XPNPEP1 | Q9NQW7 | 1/20 | 0.34 |
| ▸ | ECE1 | P42892 | 1/20 | 0.33 |
| ▸ | CFD | P00746 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13182580 | 1.00 | ANPEP (0.58) | ANPEPMMP2GBA2MMP1MMP3 | |
| SCHEMBL6819743 | 0.88 | ALDH1A1 (0.48) | ANPEPMMP2GBA2LMNAPOLB | |
| SCHEMBL10084211 | 0.88 | ALDH1A1 (0.48) | ANPEPMMP2GBA2LMNAPOLB | |
| SCHEMBL28819356 | 0.88 | ALDH1A1 (0.48) | ANPEPMMP2GBA2LMNAPOLB | |
| SCHEMBL16758164 | 0.88 | ALDH1A1 (0.48) | ANPEPMMP2GBA2LMNAPOLB | |
| SCHEMBL10085243 | 0.86 | GBA2 (0.42) | ANPEPMMP2GBA2MMP1MMP3 | |
| SCHEMBL10084421 | 0.86 | GBA2 (0.42) | ANPEPMMP2GBA2MMP1MMP3 | |
| SCHEMBL16619795 | 0.86 | GBA2 (0.46) | ANPEPMMP2GBA2LMNAPOLB | |
| SCHEMBL28233898 | 0.84 | GBA2 (0.40) | ANPEPMMP2GBA2LMNAPOLB | |
| SCHEMBL15719677 | 0.84 | PEPD (0.47) | ANPEPMMP2GBA2MMP1MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9469609-B2 | Synthesis of pyrrolidine compounds | ZEALAND PHARMA A/S (DK) | 2016-10-18 | — | — | US | disclosed |
| US-20150322007-A1 | SYNTHESIS OF PYRROLIDINE COMPOUNDS | ZEALAND PHARMA A/S (DK) | 2015-11-12 | — | — | US | disclosed |
| US-8927590-B2 | Synthesis of pyrrolidine compounds | ZEALAND PHARMA A/S (DK) | 2015-01-06 | — | — | US | disclosed |
| US-20130053344-A1 | SYNTHESIS OF PYRROLIDINE COMPOUNDS | ZEALAND PHARMA A/S (DK) | 2013-02-28 | — | — | US | disclosed |
| EP-2468724-A1 | Synthesis of pyrrolidine compounds | Zealand Pharma A/S (DK) | 2012-06-27 | — | — | EP | disclosed |
| US-20100249207-A1 | SYNTHESIS OF PYRROLIDINE COMPOUNDS | WYETH LLC (US) | 2010-09-30 | — | — | US | disclosed |
| US-20080188545-A1 | (2S,4R)-1-(2-aminoacetyl)-4-benzamidopyrrolidine-2-carboxylic acid hydrochloride monohydrate; cardiovascular disease; osteoporosis; inflammation of airway epithelium; disorders of alveolar tissue; bladder incontinence; impaired hearing; endothelial lesions | ZEALAND PHARMA A/S (DK) | 2008-08-07 | — | — | US | disclosed |
| WO-2008079266-A2 | SYNTHESIS OF PYRROLIDINE COMPOUNDS | WYETH (US) | 2008-07-03 | — | — | WO | disclosed |
| WO-2000001714-A1 | EFFLUX PUMP INHIBITORS | MICROCIDE PHARMACEUTICALS, INC. (US) | 2000-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053344-A1 | SYNTHESIS OF PYRROLIDINE COMPOUNDS | CPS1, DHPS, DDC | ANPEP 686/4885MMP2 3894/4885GBA2 1465/4885 |
| US-20150322007-A1 | SYNTHESIS OF PYRROLIDINE COMPOUNDS | CPS1, DHPS, DDC | ANPEP 686/4885MMP2 3894/4885GBA2 1465/4885 |
| US-20080188545-A1 | (2S,4R)-1-(2-aminoacetyl)-4-benzamidopyrrolidine-2-carboxylic acid hydrochloride monohydrate; cardiovascular disease; osteoporosis; inflammation of airway epithelium; disorders of alveolar tissue; bladder incontinence; impaired hearing; endothelial lesions | GLS, COL2A1, MYOC | ANPEP 347/4885MMP2 970/4885GBA2 4014/4885 |
| US-20100249207-A1 | SYNTHESIS OF PYRROLIDINE COMPOUNDS | CPS1, DHPS, DDC | ANPEP 686/4885MMP2 3894/4885GBA2 1465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.